Cel-Sci shares jump after FDA lifts hold; New upstart is looking for Euro marketing pacts with biotech
⇨ Shares at microcap biotech Cel-Sci $CVM jumped 36% after the biotech announced that the FDA has lifted the clinical hold on its Phase III study of Multikine for head and neck cancer. Researchers have recruited 928 frontline patients for this study. The primary endpoint is a 10% increase in overall survival.
⇨ Here’s a new option for biotechs to take a look at. A group that includes ex-Biogen CEO Jim Mullen has formed a new company — cleverly named Vicarius — which is looking to do deals where it undertakes the European marketing for new drugs. This is one possible alternative to going it alone or outlicensing European marketing rights for some loess-than-ideal returns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.